SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly
traded cannabis company in the U.S., today announced that a recent clinical study conducted by renowned Mexico neurologist, Dr.
Carlos G. Aguirre-Velazquez, successfully utilized its flagship THC-free product Real Scientific Hemp Oil-X™ (RSHO-X™).
The study targeted the reduction in frequency, intensity and duration of convulsive crises in people with tuberous sclerosis
complex (TSC) and saw promising results from cannabidiol (CBD) as a treatment for patients with TSC. Other factors observed in
the study were quality of life, dependence on heavy prescription drugs and long-term sustainability of treatment with CBD.
The trial was comprised of patients with varying forms of epilepsy, with the majority having TSC, a genetic disorder
characterized by the growth of noncancerous (benign tumors) in many parts of the body, including the brain, which can lead to
convulsive crises. TSC affects 1 million people worldwide, 50,000 in the U.S. and 20,000 in Mexico.
Results from the trial showed that 60% of participants who used CBD products saw a clinically significant (80-100%) reduction
in the frequency of their seizures. Additionally, quality of life metrics such as mood, appetite
and cognition saw substantial increases among the patients using CBD. Finally, no serious side effects were reported, only mild
ones such as drowsiness and increase in appetite, which eventually disappeared with the need to reduce the dose.
The study concludes that, "The experience of parents and patients with medicinal cannabis
(CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary
to TSC."
"Each time new study results are published showing the positive effects of CBD on a new indication is a victory for showcasing
the therapeutic benefits of CBD and people around the world suffering from a multitude of debilitating conditions," said Dr.
Stuart Titus, CEO of Medical Marijuana, Inc. "We congratulate Dr. Aguirre for his work in
unveiling, like he did in this study, that not only is CBD effective in relieving seizures, but also exhibiting that CBD can be
used over long periods of time without harm, compared to antiepileptic or broad-spectrum steroids that can have dangerous side
effects if used for several years, including vision and damage to major organs."
HempMeds® Mexico's zero-THC product RSHO-X™ was the first-ever cannabis product to
receive approval from the federal government of Mexico, COFEPRIS, for importation into the
country. Dr. Aguirre will present his findings to an online audience on Thursday, October 12, 2017
on a live event on the Por Grace Facebook at
11:00am CDT (9:00am PDT). For more information and to view the
full results of Dr. Aguirre's study, click
here.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to
receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds®
Mexico plans to work directly with the Mexican government to safely and legally provide access
to CBD hemp oil products. For more information, please review the company's website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
We are a company of
firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to
source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial
spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses,
while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks,
uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to
diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United
States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
View original content with multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-mexico-announces-results-from-clinical-study-including-real-scientific-hemp-oil-x-rsho-x-on-patients-with-tuberous-sclerosis-complex-tsc-300535141.html
SOURCE Medical Marijuana, Inc.